Replies to post #120708 on Biotech Values

[DewDiligence]

In Elan's primary analysis, they used a linear model to measure benefit of Bapineuzumab over PBO, instead of calculating benefit on actual observed data.

I do not understand precisely what this means. Can you elaborate?

[genisi]

One more concern I see about bapi phase II data is the lack of dose response related to efficacy* (in contrast to safety where vasogenic edema was dose-related).

*Both efficacy and vasogenic edema were related to ApoE4.